<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Clin. Infect. Dis</journal-id><journal-id journal-id-type="publisher-id">cid</journal-id><journal-id journal-id-type="hwp">cid</journal-id><journal-title-group><journal-title>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America</journal-title></journal-title-group><issn pub-type="ppub">1058-4838</issn><issn pub-type="epub">1537-6591</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22610930</article-id><article-id pub-id-type="pmc">3412691</article-id><article-id pub-id-type="doi">10.1093/cid/cis486</article-id><article-id pub-id-type="publisher-id">cis486</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles and Commentaries</subject></subj-group><subj-group subj-group-type="category-oup-series"><subject>Editor's Choice</subject></subj-group></article-categories><title-group><article-title>Doxycycline Improves Filarial Lymphedema Independent of Active Filarial
Infection: A Randomized Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mand</surname><given-names>Sabine</given-names></name><author-comment><title>a</title><p>S. M., A. Y. D., and U. K. contributed equally to this study.</p></author-comment><xref ref-type="aff" rid="af1">1</xref><!--<email>ute.klarmann@ukb.uni-bonn.de</email>--><xref ref-type="corresp" rid="d640850e279"/></contrib><contrib contrib-type="author"><name><surname>Debrah</surname><given-names>Alexander Yaw</given-names></name><author-comment><title>a</title><p>S. M., A. Y. D., and U. K. contributed equally to this study.</p></author-comment><xref ref-type="aff" rid="af3">3</xref><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Klarmann</surname><given-names>Ute</given-names></name><author-comment><title>a</title><p>S. M., A. Y. D., and U. K. contributed equally to this study.</p></author-comment><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Batsa</surname><given-names>Linda</given-names></name><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Marfo-Debrekyei</surname><given-names>Yeboah</given-names></name><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Kwarteng</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Specht</surname><given-names>Sabine</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Belda-Domene</surname><given-names>Aurea</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fimmers</surname><given-names>Rolf</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Adjei</surname><given-names>Ohene</given-names></name><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hoerauf</surname><given-names>Achim</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib></contrib-group><aff id="af1">
<label>1</label>
<addr-line>Institute for Medical Microbiology, Immunology and Parasitology</addr-line>
</aff><aff id="af2">
<label>2</label>
<addr-line>Institute for Medical Biometry, Informatics and Epidemiology</addr-line>,
<institution>University
Hospital Bonn</institution>, <country>Germany</country></aff><aff id="af3">
<label>3</label>
<addr-line>Faculty of Allied Health Sciences</addr-line>
</aff><aff id="af4">
<label>4</label>
<addr-line>Komfo Anokye Teaching Hospital, School of Medical Sciences</addr-line>,
<institution>Kwame Nkrumah
University of Science and Technology</institution></aff><aff id="af5">
<label>5</label>
<addr-line>Kumasi Centre for Collaborative Research in Tropical Medicine</addr-line>,
<country>Ghana</country></aff><aff id="af6">
<label>6</label>
<addr-line>Liverpool School of Tropical Medicine</addr-line>, <country>United
Kingdom</country></aff><author-notes><fn id="FN1"><label>a</label><p>S. M., A. Y. D., and U. K. contributed equally to this study.</p></fn><corresp id="d640850e279">Correspondence: Ute Klarmann, MD, Institute for Medical
Microbiology, Immunology and Parasitology, University Hospital Bonn, Sigmund-Freud-Strasse
25, 53105 Bonn, Germany (<email>ute.klarmann@ukb.uni-bonn.de</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>1</day><month>9</month><year>2012</year></pub-date><pub-date pub-type="epub" iso-8601-date="2012-05-18"><day>18</day><month>5</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>5</month><year>2012</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>55</volume><issue>5</issue><fpage>621</fpage><lpage>630</lpage><history><date date-type="received"><day>29</day><month>12</month><year>2011</year></date><date date-type="accepted"><day>30</day><month>4</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; The Author 2012. Published by Oxford University Press on behalf of
the Infectious Diseases Society of America. All rights reserved.</copyright-statement><copyright-year>2012</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/3.0"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License
(<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>), which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided
the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="cis486.pdf"/><abstract abstract-type="teaser"><p>Treatment with doxycycline leads to improvement of filarial lymphedema independent of
active infection (ie, patients positive or negative for circulating filarial antigen).
Therefore, doxycycline (200&#x000a0;mg/d for 6 weeks) should be considered for patients with stage
1&#x02013;3 lymphedema to improve morbidity management.</p></abstract><abstract><title>Abstract</title><p>
<bold><italic>Background.</italic></bold>&#x02003;The aim of this study was to determine whether improvement of filarial lymphedema
(LE) by doxycycline is restricted to patients with ongoing infection (positive for
circulating filarial antigen [CFA]), or whether the majority of CFA-negative patients with
LE would also show a reduction in LE severity.</p><p>
<bold><italic>Methods.</italic></bold>&#x02003;One hundred sixty-two Ghanaian participants with LE stage 1&#x02013;5 (Dreyer) were
randomized blockwise into 2 groups (CFA positive or negative) and allocated to 3 treatment
arms of 6 weeks: (1) amoxicillin (1000&#x000a0;mg/d), (2) doxycycline (200&#x000a0;mg/d), or (3) placebo
matching doxycycline. All groups received standard hygiene morbidity management. The
primary outcome was reduction of LE stages. Secondary outcomes included frequency of acute
attacks and ultrasonographic assessment of skin thickness at the ankles. Parameters were
assessed before treatment and after 3, 12, and 24 months.</p><p>
<bold><italic>Results.</italic></bold>&#x02003;Doxycycline-treated patients with LE stage 2&#x02013;3 showed significant reductions in LE
severity after 12 and 24 months, regardless of CFA status. Improvement was observed in
43.9% of doxycycline-treated patients, compared with only 3.2% and 5.6% in the amoxicillin
and placebo arms, respectively. Skin thickness was correlated with LE stage improvement.
Both doxycycline and amoxicillin were able to reduce acute dermatolymphangioadenitis
attacks.</p><p>
<bold><italic>Conclusions.</italic></bold>&#x02003;Doxycycline treatment improves mild to moderate LE independent of ongoing
infection. This finding expands the benefits of doxycycline to the entire population of
patients suffering from LE. Patients with LE stage 1&#x02013;3 should benefit from a 6-week course
of doxycycline every other year or yearly, which should be considered as an improved tool
to manage morbidity in filarial LE.</p><p>
<bold><italic>Clinical Trials Registration.</italic></bold>&#x02003;ISRCTN 90861344.</p></abstract></article-meta></front><body><p>Worldwide, 40 million persons are disabled owing to filariasis-related morbidity, with 15
million suffering from lymphedema (LE) or elephantiasis and 25 million with hydrocele.
Filarial LE is caused by infection with the lymphatic filarial nematodes, <italic>Wuchereria
bancrofti, Brugia malayi,</italic> and <italic>Brugia timori</italic> and occurs most
commonly in the legs. Patients experience a gradual and progressive development in the
severity of clinical LE, graded 1&#x02013;7 (<xref ref-type="supplementary-material" rid="sup1">Supplementary Figure 1</xref>), leading to severe disability, loss of productivity, and
social stigmatization [<xref rid="CIS486C1" ref-type="bibr">1</xref>]. Patients with LE also
experience &#x0201c;acute attacks&#x0201d; or acute dermatolymphangioadenitis, arising through secondary
microbial infection acquired through lesions in the skin [<xref rid="CIS486C2" ref-type="bibr">2</xref>].</p><p>The goals of the Global Programme to Eliminate Lymphatic Filariasis (GPELF) are (1) to
interrupt transmission by reduction of microfilaremia levels using mass drug administration
(MDA) of filaricidal drugs and (2) to provide morbidity management for those who suffer from
clinical manifestations associated with lymphatic filariasis (LF) [<xref rid="CIS486C3" ref-type="bibr">3&#x02013;5</xref>]. The first goal has been successfully approached in
areas having used diethylcarbamazine and albendazole for mass drug treatment for &#x02265;5 years but
has been met less successfully in Africa, where ivermectin and albendazole have been
administered [<xref rid="CIS486C6" ref-type="bibr">6</xref>]. During the first 10 years of the
GPELF, prevention of new morbidity has been impressive, with an estimated 22 million persons
protected from LF infection and disease, accounting for economic savings of US $24.2 billion
[<xref rid="CIS486C4" ref-type="bibr">4</xref>]. However, the goal to reduce
<italic>existing</italic> morbidity associated with chronic filarial disease has not scaled
up as rapidly as MDA, with only 33% of endemic countries introducing morbidity management in
the first decade of the GPELF [<xref rid="CIS486C1" ref-type="bibr">1</xref>]. Current
morbidity management strategies rely on improving hygiene and skin care of affected limbs,
with limb elevation, exercise, and the use of topical antibiotics and antifungal creams, which
reduces the frequency of acute attacks and can help arrest the development of LE [<xref rid="CIS486C3" ref-type="bibr">3</xref>]. We have shown elsewhere that 6 weeks of
doxycycline results in a significant amelioration of LE severity in patients with active
infection of <italic>W. bancrofti</italic> [<xref rid="CIS486C7" ref-type="bibr">7</xref>].</p><p>The present study was designed to address whether these benefits of a 6-week course of
doxycycline (200&#x000a0;mg/d) could be extended to patients negative for circulating filarial antigen
(CFA). In addition, we tested to determine whether a similar course of amoxicillin was also
effective against LE. Our results demonstrate that doxycycline improves mild to moderate LE
over 2 years. Importantly, CFA-negative patients also demonstrated significant improvement in
LE, showing that the activity of doxycycline is not confined to patients with active
infection. These results strongly promote the use of doxycycline as a new strategy for
improved morbidity management of LF.</p><sec sec-type="methods" id="s1"><title>MATERIALS AND METHODS</title><p>The trial was approved by the Committee on Human Research, Publication and Ethics at the
Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. The study conformed to
the principles of the Declaration of Helsinki 1964 (amended most recently in 2004). The
trial registration number is ISRCTN 90861344.</p><sec id="s1a"><title>Participants and Study Area</title><p>This trial was conducted in 21 endemic communities in the Nzema East and Ahanta West
districts in the western region of Ghana [<xref rid="CIS486C7" ref-type="bibr">7&#x02013;9</xref>], where MDA was started in 2001. Written informed consent was obtained from
all participants. Eligible individuals were adults of both sexes aged 18&#x02013;60 years with LE
stage 1&#x02013;5 according to the staging scheme by Dreyer [<xref rid="CIS486C5" ref-type="bibr">5</xref>], with a minimum body weight of 40&#x000a0;kg and no requirement for chronic
medication. Exclusion criteria included LE stage 6 or 7; abnormal
gamma-glutamyltransferase, alanine aminotransferase, or creatinine levels; pregnancy;
breast-feeding; intolerance to doxycycline or amoxicillin; and alcohol or drug abuse. A
clinician (S. M.) experienced in the symptoms of LE examined all consenting patients and
performed the staging as well as ultrasonography at pretreatment and follow-up
examinations.</p></sec><sec id="s1b"><title>Randomization and Masking</title><p>This was a randomized trial; the design was placebo controlled for the comparison of
doxycycline and placebo, with an additional open amoxicillin arm. Randomization was
carried out using computer-generated software. Blinding (masking) was ensured by exclusion
of study personnel performing clinical or laboratory analyses from randomization or tablet
distribution. To avoid an influence on results caused by the open amoxicillin arm, the
personnel administering the treatment (A. B. D. and Y. M. D.) did not take part in
follow-up examinations. A total of 162 patients were randomly allocated into 3 treatment
arms: (1) amoxicillin, (2) doxycycline, and (3) placebo treatment, each with 54 patients.
Before randomization, participants were stratified into those with and those without
active infection (CFA positive and CFA negative). These 2 subgroups were separately
randomized, resulting in 6 final treatment groups (Figure&#x000a0;<xref ref-type="fig" rid="CIS486F1">1</xref>, <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure 2<italic>A</italic> and <italic>B</italic></xref>). </p><fig id="CIS486F1" orientation="portrait" position="float"><label>Figure&#x000a0;1.</label><caption><p>Participant flow. Flow chart of all assessed volunteers (circulating filarial antigen
positive and negative). Abbreviations: CFA, circulating filarial antigen; USG,
ultrasonography.</p></caption><graphic xlink:href="cis48601"/></fig></sec><sec id="s1c"><title>Treatment and Follow-up</title><p>Participants received doxycycline (2 100-mg capsules daily), matching placebo, or
amoxicillin (2 500-mg tablets daily) for a total of 6 weeks. Treatment was directly
observed daily. Adverse events were recorded in the case report forms, and patients were
seen by the trial clinician (A. B. D.). Two rounds of single-dose ivermectin and
albendazole were distributed during the clinical trial within the scope of the annual MDA.
Follow-up time points were 3, 12, and 24 months after treatment onset.</p></sec><sec id="s1d"><title>Foot Care Training and Monitoring of Hygiene Measures</title><p>All patients received soap, towels, and plastic bowls for washing their legs and were
trained in foot hygiene, according to the booklet &#x0201c;New Hope&#x0201d; for persons with LE [<xref rid="CIS486C5" ref-type="bibr">5</xref>].</p></sec><sec id="s1e"><title>LE Staging</title><p>Staging of LE was performed according to the &#x0201c;Basic Lymphedema Management&#x0201d; guidelines
established by G. Dreyer and colleagues [<xref rid="CIS486C5" ref-type="bibr">5</xref>]
(<xref ref-type="supplementary-material" rid="sup1">Supplementary Figure 1</xref>). To
allow comparisons of LE staging in patients with either one or both legs affected, the
following approach was employed: (1) if only one leg showed LE, this leg was analyzed; (2)
if both legs were affected, the leg with the lower stage is reported; (3) if both legs
were affected showing equal stages, either the left or the right leg was analyzed after
computer-generated randomization.</p></sec><sec id="s1f"><title>Monitoring of Acute Attacks</title><p>Acute attacks were defined as pain, lymph node swelling (femoral and/or inguinal), fever,
and peeling of the skin on the affected leg after the resolving of the febrile attack
(<xref ref-type="supplementary-material" rid="sup1">Supplementary Figure 3</xref>). The
history regarding acute attacks was evaluated based on booklets kept by the patients and
questionnaires filled out by the research team at every visit. Each study participant was
asked in detail about the number and duration of attacks, fever, lymph node swelling, and
peeling of the skin to differentiate general pain in affected legs from genuine acute
attacks.</p></sec><sec id="s1g"><title>Microfilaremia, Antigenemia and Vascular Endothelial Growth Factors</title><p>For quantification of microfilariae in the blood the Whatman Nucleopore filter method was
applied using 10-mL samples of night blood before treatment and at follow-up. Levels of
<italic>W. bancrofti</italic> CFA were determined using the TropBio enzyme-linked
immunosorbent assay (ELISA) test (TropBio) [<xref rid="CIS486C7" ref-type="bibr">7</xref>]. Levels of vascular endothelial growth factor (VEGF) C and soluble VEGF
receptor (VEGFR) 3 were measured from plasma samples using Quantikine or DuoSet ELISA
kits, respectively (R&#x00026;D systems).</p></sec><sec id="s1h"><title>Circumference Measurement of Legs</title><p>Leg circumferences were determined using a tape measure. Measurements were performed at
10&#x000a0;cm from the large toe and 12, 20, and 30&#x000a0;cm from the sole of the foot, as described
elsewhere [<xref rid="CIS486C10" ref-type="bibr">10</xref>, <xref rid="CIS486C11" ref-type="bibr">11</xref>]. Averages of the 4 measurements were determined before
treatment and at follow-up.</p></sec><sec id="s1i"><title>Ultrasound Examinations of the Ankles</title><p>Ultrasonography was performed between 2 and 7 PM using a SonoSite 180 PLUS hand-carried
ultrasound system (SonoSite) equipped with a 38-mm 5&#x02013;10-MHz linear-array transducer [<xref rid="CIS486C12" ref-type="bibr">12</xref>]. Patients were scanned sitting with stretched
legs and feet perpendicular to the legs. The transducer was positioned at the top of the
malleolus (ankle) and kept at a 90&#x000b0; angle to the skin surface in transverse sections. The
head of tibia or fibula had to be visible, and the malleolus had to appear as a sharp line
(<xref ref-type="supplementary-material" rid="sup1">Supplementary Figure 1</xref>) to
permit reproducibility. The thickness of the tissue (subcutis, dermis, and epidermis) was
measured from the malleolus to the skin surface. Lateral and medial malleoli of both legs
were measured before treatment and at follow-up.</p></sec><sec id="s1j"><title>Statistical Analysis</title><p>To compare between the treatment arms, the intraindividual differences in staging or
measurements between the respective follow-up and pretreatment findings were first
calculated. Kruskal-Wallis tests followed by Mann-Whitney <italic>U</italic> tests or
Fisher's exact test were used to compare between the treatment arms. The Wilcoxon signed
rank test or the McNemar test were chosen for comparing pretreatment with follow-up
results in one treatment arm. Correlations were done using the Spearman rank test.
Differences between the treatment arms in the survival curve (Kaplan-Meier) were analyzed
with the log-rank test.</p><p>To confirm the results of the per-protocol analyses (patients who completed the treatment
and were present for the respective follow-up visit) an intention-to-treat (ITT) analysis
was carried out with all patients who started treatment (missing values were filled in
using the "last observation carried forward" method). Analyses were done using PASW
statistics 18.0 software (IBM) and SAS 9.2 software (SAS).</p></sec></sec><sec sec-type="results" id="s2"><title>RESULTS</title><sec id="s2a"><title>Participants</title><p>From a recruitment pool of 205 patients with LE, 162 patients were stratified according
to CFA status (Figure&#x000a0;<xref ref-type="fig" rid="CIS486F1">1</xref>, <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure 2<italic>A</italic>
and <italic>B</italic></xref>). At the start of treatment, 21 patients abandoned
participation, although they had explicitly agreed to participate and had been randomized,
and 13 participants stated that they had not given correct information about age or
breast-feeding on recruitment. Along with these 34 patients, another 9 dropped out during
treatment for reasons unrelated to the study drugs.</p></sec><sec id="s2b"><title>Baseline Data</title><p>Of the 119 patients who completed the treatment, 46 (39%) were CFA positive and 73 (61%)
were CFA negative. Most of the patients had LE stage 2 (44.5%) or 3 (47.9%). The mean age
was 47.7&#x000a0;&#x000b1;&#x000a0;10.8 years. CFA-negative patients had on average a longer history of LE
development than CFA-positive patients (<italic>P&#x000a0;</italic>=&#x000a0;.029). There was no
difference among the treatment arms regarding compliance with MDA (Table&#x000a0;<xref ref-type="table" rid="CIS486TB1">1</xref>). </p><table-wrap id="CIS486TB1" orientation="portrait" position="float"><label>Table&#x000a0;1.</label><caption><p>Baseline Data</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Variable</th><th align="left" colspan="1" rowspan="1">Total</th><th align="left" colspan="1" rowspan="1">Doxycycline</th><th align="left" colspan="1" rowspan="1">Amoxicillin</th><th align="left" colspan="1" rowspan="1">Placebo</th><th align="left" colspan="1" rowspan="1">
<italic>P</italic> Value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Patients (male/female), No.</td><td colspan="1" rowspan="1">119 (34/85)</td><td colspan="1" rowspan="1">46 (10/36)</td><td colspan="1" rowspan="1">35 (9/26)</td><td colspan="1" rowspan="1">38 (15/23)</td><td colspan="1" rowspan="1">.198<sup>a</sup></td></tr><tr><td colspan="1" rowspan="1">&#x02003;CFA positive</td><td colspan="1" rowspan="1">46 (17/29)</td><td colspan="1" rowspan="1">19 (5/14)</td><td colspan="1" rowspan="1">13 (6/7)</td><td colspan="1" rowspan="1">14 (6/8)</td><td colspan="1" rowspan="1">.471<sup>a</sup></td></tr><tr><td colspan="1" rowspan="1">&#x02003;CFA negative</td><td colspan="1" rowspan="1">73 (17/56)</td><td colspan="1" rowspan="1">27 (5/22)</td><td colspan="1" rowspan="1">22 (3/19)</td><td colspan="1" rowspan="1">24 (9/15)</td><td colspan="1" rowspan="1">.153<sup>a</sup></td></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage 1</td><td colspan="1" rowspan="1">2 (0/2)</td><td colspan="1" rowspan="1">1 (0/1)</td><td colspan="1" rowspan="1">1 (0/1)</td><td colspan="1" rowspan="1">&#x000a0;0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage 2</td><td colspan="1" rowspan="1">53 (16/37)</td><td colspan="1" rowspan="1">20 (5/15)</td><td colspan="1" rowspan="1">18 (4/14)</td><td colspan="1" rowspan="1">15 (7/8)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage 3</td><td colspan="1" rowspan="1">57 (15/42)</td><td colspan="1" rowspan="1">23 (4/19)</td><td colspan="1" rowspan="1">15 (5/10)</td><td colspan="1" rowspan="1">19 (6/13)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage 4</td><td colspan="1" rowspan="1">1 (0/1)</td><td colspan="1" rowspan="1">1 (0/1)</td><td colspan="1" rowspan="1">&#x000a0;0</td><td colspan="1" rowspan="1">&#x000a0;0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage 5</td><td colspan="1" rowspan="1">6 (3/3)</td><td colspan="1" rowspan="1">1 (1/0)</td><td colspan="1" rowspan="1">1 (0/1)</td><td colspan="1" rowspan="1">4 (2/2)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Age,&#x000a0;mean&#x000a0;&#x000b1;&#x000a0;SD, years</td><td colspan="1" rowspan="1">47.7&#x000a0;&#x000b1;&#x000a0;10.8</td><td colspan="1" rowspan="1">46.1&#x000a0;&#x000b1;&#x000a0;11.6</td><td colspan="1" rowspan="1">51.3&#x000a0;&#x000b1;&#x000a0;9.1</td><td colspan="1" rowspan="1">46.3&#x000a0;&#x000b1;&#x000a0;10.9</td><td colspan="1" rowspan="1">.045<sup>b</sup></td></tr><tr><td colspan="1" rowspan="1">&#x02003;CFA positive</td><td colspan="1" rowspan="1">49.7&#x000a0;&#x000b1;&#x000a0;12.1</td><td colspan="1" rowspan="1">45.5&#x000a0;&#x000b1;&#x000a0;13.9</td><td colspan="1" rowspan="1">56.0&#x000a0;&#x000b1;&#x000a0;5.6</td><td colspan="1" rowspan="1">49.4&#x000a0;&#x000b1;&#x000a0;12.1</td><td colspan="1" rowspan="1">.045<sup>b</sup></td></tr><tr><td colspan="1" rowspan="1">&#x02003;CFA negative</td><td colspan="1" rowspan="1">46.5&#x000a0;&#x000b1;&#x000a0;9.8</td><td colspan="1" rowspan="1">46.5&#x000a0;&#x000b1;&#x000a0;9.9</td><td colspan="1" rowspan="1">48.6&#x000a0;&#x000b1;&#x000a0;9.7</td><td colspan="1" rowspan="1">44.5&#x000a0;&#x000b1;&#x000a0;9.9</td><td colspan="1" rowspan="1">.304<sup>b</sup></td></tr><tr><td colspan="1" rowspan="1">Duration of LE, mean&#x000a0;&#x000b1;&#x000a0;SD, years</td><td colspan="1" rowspan="1">13.8&#x000a0;&#x000b1;&#x000a0;12.3</td><td colspan="1" rowspan="1">13.7&#x000a0;&#x000b1;&#x000a0;11.8</td><td colspan="1" rowspan="1">14.6&#x000a0;&#x000b1;&#x000a0;14.9</td><td colspan="1" rowspan="1">13.3&#x000a0;&#x000b1;&#x000a0;10.5</td><td colspan="1" rowspan="1">.893<sup>b</sup></td></tr><tr><td colspan="1" rowspan="1">&#x02003;CFA positive</td><td colspan="1" rowspan="1">11.5&#x000a0;&#x000b1;&#x000a0;12.7</td><td colspan="1" rowspan="1">9.3&#x000a0;&#x000b1;&#x000a0;10.2</td><td colspan="1" rowspan="1">12.2&#x000a0;&#x000b1;&#x000a0;16.5</td><td colspan="1" rowspan="1">13.7&#x000a0;&#x000b1;&#x000a0;12.3</td><td colspan="1" rowspan="1">.475<sup>b</sup></td></tr><tr><td colspan="1" rowspan="1">&#x02003;CFA negative</td><td colspan="1" rowspan="1">15.3&#x000a0;&#x000b1;&#x000a0;11.9</td><td colspan="1" rowspan="1">16.9&#x000a0;&#x000b1;&#x000a0;11.9</td><td colspan="1" rowspan="1">16.0&#x000a0;&#x000b1;&#x000a0;14.1</td><td colspan="1" rowspan="1">13.0&#x000a0;&#x000b1;&#x000a0;9.5</td><td colspan="1" rowspan="1">.554<sup>b</sup></td></tr><tr><td colspan="1" rowspan="1">MDA/total, No. (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;2006</td><td colspan="1" rowspan="1">87/117 (74)</td><td colspan="1" rowspan="1">31/46 (67.4)</td><td colspan="1" rowspan="1">28/34 (82.4)</td><td colspan="1" rowspan="1">28/37 (75.7)</td><td colspan="1" rowspan="1">.329<sup>a</sup></td></tr><tr><td colspan="1" rowspan="1">&#x02003;2007</td><td colspan="1" rowspan="1">85/115 (74)</td><td colspan="1" rowspan="1">30/44 (68.2)</td><td colspan="1" rowspan="1">27/34 (79.4)</td><td colspan="1" rowspan="1">28/37 (75.7)</td><td colspan="1" rowspan="1">.535<sup>a</sup></td></tr><tr><td colspan="1" rowspan="1">&#x02003;2008</td><td colspan="1" rowspan="1">75/109 (69)</td><td colspan="1" rowspan="1">25/41 (61.0)</td><td colspan="1" rowspan="1">24/31 (77.4)</td><td colspan="1" rowspan="1">26/37 (70.3)</td><td colspan="1" rowspan="1">.347<sup>a</sup></td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: CFA, circulating filarial antigen; LE, lymphedema; MDA, mass drug
administration (ivermectin plus albendazole); SD, standard deviation.</p></fn><fn><p>
<sup>a</sup> Fisher's exact test.</p></fn><fn><p>
<sup>b</sup> Kruskal-Wallis test.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2c"><title>Primary Outcome Analysis</title><sec id="s2c1"><title>LE Staging</title><p>Figures&#x000a0;<xref ref-type="fig" rid="CIS486F2">2</xref><italic>A</italic>&#x02013;<italic>C</italic> show changes in LE stages before
treatment compared with 12 and 24 months after treatment. The affected legs of patients
in the doxycycline group reverted to a lower stage at 12 and 24 months
(<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>.002; Table&#x000a0;<xref ref-type="table" rid="CIS486TB2">2</xref>), whereas they progressed to a higher stage in the
amoxicillin and placebo groups (<italic>P&#x000a0;</italic>=&#x000a0;.012 and <italic>P&#x000a0;</italic>=&#x000a0;.001
respectively). Comparing all groups at 24 months (Figure&#x000a0;<xref ref-type="fig" rid="CIS486F2">2</xref><italic>A</italic>), there was a difference between doxycycline
and amoxicillin groups (<italic>P&#x000a0;</italic>&#x0003c;&#x000a0;.001) and between doxycycline and
placebo groups (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;.001). The ITT analysis confirmed these results
(<xref ref-type="supplementary-material" rid="sup1">Supplementary Table 2,
Supplementary Figure&#x000a0;4)</xref>. However, although there was no significant difference
between amoxicillin and placebo groups at 24 months in the per-protocol analysis, a
better outcome in the amoxicillin group compared with placebo could be detected in the
ITT analysis (<italic>P&#x000a0;</italic>=&#x000a0;.034). Because 92.4% of the patients had LE stage 2
or 3, additional per-protocol and ITT analyses were carried out to follow these group of
patients only, confirming the overall analyses (<xref ref-type="supplementary-material" rid="sup1">Supplementary Tables 3 and 4</xref>). </p><table-wrap id="CIS486TB2" orientation="portrait" position="float"><label>Table&#x000a0;2.</label><caption><p>Lymphedema Staging: Descriptive Statistics (Per-Protocol Analysis)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Pretreatment</th><th align="left" colspan="1" rowspan="1">3-Month Follow-up</th><th align="left" colspan="1" rowspan="1">12-Month Follow-up</th><th align="left" colspan="1" rowspan="1">24-Month Follow-up</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Treatment A: doxycycline (200&#x000a0;mg/d)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">CFA positive and negative</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Patients, No.</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">41</td></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage, mean&#x000a0;&#x000b1;&#x000a0;SD (range)</td><td colspan="1" rowspan="1">2.6&#x000a0;&#x000b1;&#x000a0;0.7 (1&#x02013;5)</td><td colspan="1" rowspan="1">2.6&#x000a0;&#x000b1;&#x000a0;0.8 (1&#x02013;6)</td><td colspan="1" rowspan="1">2.4&#x000a0;&#x000b1;&#x000a0;1.2 (0&#x02013;6)</td><td colspan="1" rowspan="1">2.2&#x000a0;&#x000b1;&#x000a0;1.2 (0&#x02013;6)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage, median (25th; 75th percentile)</td><td colspan="1" rowspan="1">3 (2; 3)</td><td colspan="1" rowspan="1">3 (2; 3)</td><td colspan="1" rowspan="1">2 (2; 3)</td><td colspan="1" rowspan="1">2 (1; 3)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;<italic>P</italic><sup>a</sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">.48</td><td colspan="1" rowspan="1">.067</td><td colspan="1" rowspan="1">.002</td></tr><tr><td colspan="1" rowspan="1">Subgroup: CFA positive before treatment</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Patients, No.</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">17</td></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage, mean&#x000a0;&#x000b1;&#x000a0;SD (range)</td><td colspan="1" rowspan="1">2.6&#x000a0;&#x000b1;&#x000a0;0.8 (1&#x02013;5)</td><td colspan="1" rowspan="1">2.6&#x000a0;&#x000b1;&#x000a0;1.1 (1&#x02013;6)</td><td colspan="1" rowspan="1">2.6&#x000a0;&#x000b1;&#x000a0;1.6 (0&#x02013;6)</td><td colspan="1" rowspan="1">2.2&#x000a0;&#x000b1;&#x000a0;1.4 (0&#x02013;6)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage, median (25th; 75th percentile)</td><td colspan="1" rowspan="1">3 (2; 3)</td><td colspan="1" rowspan="1">3 (2; 3)</td><td colspan="1" rowspan="1">3 (2; 3)</td><td colspan="1" rowspan="1">2 (1; 3)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;<italic>P</italic><sup>a</sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">.564</td><td colspan="1" rowspan="1">.861</td><td colspan="1" rowspan="1">.058</td></tr><tr><td colspan="1" rowspan="1">Subgroup: CFA negative before treatment</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Patients, No.</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">24</td></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage, mean&#x000a0;&#x000b1;&#x000a0;SD (range)</td><td colspan="1" rowspan="1">2.6&#x000a0;&#x000b1;&#x000a0;0.7 (2&#x02013;4)</td><td colspan="1" rowspan="1">2.5&#x000a0;&#x000b1;&#x000a0;0.7 (1&#x02013;4)</td><td colspan="1" rowspan="1">2.2&#x000a0;&#x000b1;&#x000a0;0.9 (0&#x02013;4)</td><td colspan="1" rowspan="1">2.1&#x000a0;&#x000b1;&#x000a0;1.0 (0&#x02013;4)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage, median (25th; 75th percentile)</td><td colspan="1" rowspan="1">3 (2; 3)</td><td colspan="1" rowspan="1">2 (2; 3)</td><td colspan="1" rowspan="1">2 (2; 3)</td><td colspan="1" rowspan="1">2 (1.25; 3)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;<italic>P</italic><sup>a</sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">.18</td><td colspan="1" rowspan="1">.02</td><td colspan="1" rowspan="1">.013</td></tr><tr><td colspan="1" rowspan="1">Treatment B: amoxicillin (1000&#x000a0;mg/d)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">CFA positive and negative</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Patients, No.</td><td colspan="1" rowspan="1">35</td><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">31</td></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage, mean&#x000a0;&#x000b1;&#x000a0;SD (range)</td><td colspan="1" rowspan="1">2.5&#x000a0;&#x000b1;&#x000a0;0.7 (1&#x02013;5)</td><td colspan="1" rowspan="1">2.5&#x000a0;&#x000b1;&#x000a0;0.7 (1&#x02013;6)</td><td colspan="1" rowspan="1">2.7&#x000a0;&#x000b1;&#x000a0;1.3 (1&#x02013;6)</td><td colspan="1" rowspan="1">3.0&#x000a0;&#x000b1;&#x000a0;1.4 (1&#x02013;6)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage, median (25th; 75th percentile)</td><td colspan="1" rowspan="1">2 (2; 3)</td><td colspan="1" rowspan="1">2 (2; 3)</td><td colspan="1" rowspan="1">2 (2; 3)</td><td colspan="1" rowspan="1">2 (2; 4)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;<italic>P</italic><sup>a</sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">.38</td><td colspan="1" rowspan="1">.012</td></tr><tr><td colspan="1" rowspan="1">Subgroup: CFA positive before treatment</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Patients, No.</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage, mean&#x000a0;&#x000b1;&#x000a0;SD (range)</td><td colspan="1" rowspan="1">2.4&#x000a0;&#x000b1;&#x000a0;0.7 (1&#x02013;3)</td><td colspan="1" rowspan="1">2.4&#x000a0;&#x000b1;&#x000a0;0.7 (1&#x02013;3)</td><td colspan="1" rowspan="1">2.3&#x000a0;&#x000b1;&#x000a0;0.8 (1&#x02013;3)</td><td colspan="1" rowspan="1">2.7&#x000a0;&#x000b1;&#x000a0;1.0 (1&#x02013;4)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage, median (25th; 75th percentile)</td><td colspan="1" rowspan="1">2 (2; 3)</td><td colspan="1" rowspan="1">2 (2; 3)</td><td colspan="1" rowspan="1">2 (2; 3)</td><td colspan="1" rowspan="1">2.5 (2; 3.75)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;<italic>P</italic><sup>a</sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">.157</td><td colspan="1" rowspan="1">.083</td></tr><tr><td colspan="1" rowspan="1">Subgroup: CFA negative before treatment</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Patients, No.</td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">19</td></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage, mean&#x000a0;&#x000b1;&#x000a0;SD (range)</td><td colspan="1" rowspan="1">2.6&#x000a0;&#x000b1;&#x000a0;0.7 (2&#x02013;5)</td><td colspan="1" rowspan="1">2.6&#x000a0;&#x000b1;&#x000a0;1.0 (1&#x02013;6)</td><td colspan="1" rowspan="1">2.9&#x000a0;&#x000b1;&#x000a0;1.5 (1&#x02013;6)</td><td colspan="1" rowspan="1">3.2&#x000a0;&#x000b1;&#x000a0;1.6 (1&#x02013;6)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage, median (25th; 75th percentile)</td><td colspan="1" rowspan="1">2 (2; 3)</td><td colspan="1" rowspan="1">2 (2; 3)</td><td colspan="1" rowspan="1">2 (2; 3)</td><td colspan="1" rowspan="1">2 (2; 5)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;<italic>P</italic><sup>a</sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">.129</td><td colspan="1" rowspan="1">.04</td></tr><tr><td colspan="1" rowspan="1">Treatment C: placebo</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">CFA positive and negative</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Patients, No.</td><td colspan="1" rowspan="1">38</td><td colspan="1" rowspan="1">36</td><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">36</td></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage, mean&#x000a0;&#x000b1;&#x000a0;SD (range)</td><td colspan="1" rowspan="1">2.8&#x000a0;&#x000b1;&#x000a0;0.8 (2&#x02013;5)</td><td colspan="1" rowspan="1">3.0&#x000a0;&#x000b1;&#x000a0;1.3 (1&#x02013;6)</td><td colspan="1" rowspan="1">3.4&#x000a0;&#x000b1;&#x000a0;1.6 (0&#x02013;6)</td><td colspan="1" rowspan="1">3.6&#x000a0;&#x000b1;&#x000a0;1.5 (0&#x02013;6)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage, median (25th; 75th percentile)</td><td colspan="1" rowspan="1">3 (2; 3)</td><td colspan="1" rowspan="1">3 (2; 3)</td><td colspan="1" rowspan="1">3 (2; 5)</td><td colspan="1" rowspan="1">3 (3; 4.75)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;<italic>P</italic><sup>a</sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">.206</td><td colspan="1" rowspan="1">.02</td><td colspan="1" rowspan="1">.001</td></tr><tr><td colspan="1" rowspan="1">Subgroup: CFA positive before treatment</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Patients, No.</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">13</td></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage, mean&#x000a0;&#x000b1;&#x000a0;SD (range)</td><td colspan="1" rowspan="1">2.9&#x000a0;&#x000b1;&#x000a0;1.2 (2&#x02013;5)</td><td colspan="1" rowspan="1">3.1&#x000a0;&#x000b1;&#x000a0;1.4 (2&#x02013;6)</td><td colspan="1" rowspan="1">3.7&#x000a0;&#x000b1;&#x000a0;2.0 (0&#x02013;6)</td><td colspan="1" rowspan="1">3.6&#x000a0;&#x000b1;&#x000a0;2.0 (0&#x02013;6)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage, median (25th; 75th percentile)</td><td colspan="1" rowspan="1">2.5 (2; 3.5)</td><td colspan="1" rowspan="1">3 (2; 4)</td><td colspan="1" rowspan="1">3 (2; 6)</td><td colspan="1" rowspan="1">3 (2; 6)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;<italic>P</italic><sup>a</sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">.317</td><td colspan="1" rowspan="1">.141</td><td colspan="1" rowspan="1">.168</td></tr><tr><td colspan="1" rowspan="1">Subgroup: CFA negative before treatment</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Patients, No.</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">23</td></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage, mean&#x000a0;&#x000b1;&#x000a0;SD (range)</td><td colspan="1" rowspan="1">2.8&#x000a0;&#x000b1;&#x000a0;0.7 (2&#x02013;5)</td><td colspan="1" rowspan="1">2.9&#x000a0;&#x000b1;&#x000a0;1.2 (1&#x02013;6)</td><td colspan="1" rowspan="1">3.3&#x000a0;&#x000b1;&#x000a0;1.4 (2&#x02013;6)</td><td colspan="1" rowspan="1">3.6&#x000a0;&#x000b1;&#x000a0;1.2 (2&#x02013;6)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;LE stage, median (25th; 75th percentile)</td><td colspan="1" rowspan="1">3 (2; 3)</td><td colspan="1" rowspan="1">3 (2; 3)</td><td colspan="1" rowspan="1">3 (2; 3)</td><td colspan="1" rowspan="1">3 (3; 4)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;<italic>P</italic><sup>a</sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">.317</td><td colspan="1" rowspan="1">.046</td><td colspan="1" rowspan="1">.001</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: CFA, circulating filarial antigen; LE, lymphedema; SD, standard
deviation.</p></fn><fn><p>
<sup>a</sup>
<italic>P</italic> value for comparison between staging before treatment and at
follow-up time point (Wilcoxon signed rank test).</p></fn></table-wrap-foot></table-wrap><fig id="CIS486F2" orientation="portrait" position="float"><label>Figure&#x000a0;2.</label><caption><p>Lymphedema (LE) staging. Differences in LE severity at 12 and 24 months compared
with pretreatment severity is&#x000a0;shown for each treatment group, according to
per-protocol analysis. <italic>A,</italic> Box plots for all patients. <italic>B,
C,</italic> Differences for the circulating filarial antigen (CFA)&#x02013;positive
(<italic>B</italic>) and CFA-negative (<italic>C</italic>) subgroups. For all
figure parts, 0 denotes no change in LE stage, changes to &#x0003c;0 denote a decrease to
lower LE stages, and changes to &#x0003e;0 denote an increase to higher LE stages.
Abbreviation: LE, lymphedema.</p></caption><graphic xlink:href="cis48602"/></fig><fig id="CIS486F3" orientation="portrait" position="float"><label>Figure&#x000a0;3.</label><caption><p>Kaplan-Meier curves showing occurrence of acute attacks after treatment end for
each treatment arm. Arrows denote follow-up time points. The following significant
differences between the 3 treatment arms were detected at 3 months: amoxicillin
versus doxycycline (<italic>P</italic>&#x000a0;=&#x000a0;.018) and amoxicillin versus placebo
(<italic>P</italic>&#x000a0;=&#x000a0;.007); at 12 months: doxycycline versus placebo
(<italic>P</italic>&#x000a0;=&#x000a0;.012) and amoxicillin versus placebo
(<italic>P</italic>&#x000a0;=&#x000a0;.007); and at 24 months: doxycycline versus placebo
(<italic>P</italic>&#x000a0;=&#x000a0;.007).</p></caption><graphic xlink:href="cis48603"/></fig><fig id="CIS486F4" orientation="portrait" position="float"><label>Figure&#x000a0;4.</label><caption><p>Reduction in skin thickness at the ankles, as analyzed by ultrasound. Box plots
show differences in skin thickness at the ankles at 24 months compared to
pretreatment (<italic>P&#x000a0;</italic>=&#x000a0;.001 for overall difference between the 3
treatment arms; Kruskal-Wallis test).</p></caption><graphic xlink:href="cis48604"/></fig><p>Doxycycline was able to improve conditions in 36.6% of patients and halt progression in
58.5%; in 4.9% the legs became worse (Table&#x000a0;<xref ref-type="table" rid="CIS486TB3">3</xref>). This improvement was significantly superior to that seen with amoxicillin
or placebo (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;.001). In contrast, only 3.2% of patients treated
with amoxicillin showed improvement; 67.7% had a lack of progression and 29% showed
deterioration. </p><table-wrap id="CIS486TB3" orientation="portrait" position="float"><label>Table&#x000a0;3.</label><caption><p>Lymphedema Staging 24 Months After Treatment</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/></colgroup><thead><tr><th colspan="1" rowspan="1"/><th align="center" colspan="3" rowspan="1">Patients, No. (%)<hr/></th></tr><tr><th align="left" colspan="1" rowspan="1">Treatment</th><th align="left" colspan="1" rowspan="1">Improvement</th><th align="left" colspan="1" rowspan="1">Lack of Progression</th><th align="left" colspan="1" rowspan="1">Progression</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Doxycycline</td><td colspan="1" rowspan="1">15/41 (36.6)</td><td colspan="1" rowspan="1">24/41 (58.5)</td><td colspan="1" rowspan="1">2/41 (4.9)</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin</td><td colspan="1" rowspan="1">1/31 (3.2)</td><td colspan="1" rowspan="1">21/31 (67.7)</td><td colspan="1" rowspan="1">9/31 (29.0)</td></tr><tr><td colspan="1" rowspan="1">Placebo</td><td colspan="1" rowspan="1">2/36 (5.6)</td><td colspan="1" rowspan="1">14/36 (38.9)</td><td colspan="1" rowspan="1">20/36 (55.6)</td></tr></tbody></table><table-wrap-foot><fn><p>
<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;.001<sup>a</sup> for the comparison of all 3 groups.
<italic>P&#x000a0;</italic>&#x0003c;&#x000a0;.001<sup>a</sup> for doxycycline vs amoxicillin and
doxycycline vs placebo; <italic>P</italic>=&#x000a0;.042<sup>a</sup> for amoxicillin vs
placebo.</p></fn><fn><p>
<sup>a</sup> Fisher's exact test.</p></fn></table-wrap-foot></table-wrap><p>To compare the performance of the 2 antibiotics in patients with or without active
infection, the treatment arms had been divided into subgroups of CFA-positive and
CFA-negative patients. In both subgroups a significant difference in LE stages between
the treatment arms could be detected at 24 months (<italic>P&#x000a0;</italic>=&#x000a0;.016 and
<italic>P&#x000a0;</italic>&#x0003c;&#x000a0;.001, respectively; Figures&#x000a0;<xref ref-type="fig" rid="CIS486F2">2</xref><italic>B</italic> and <italic>C</italic>). In the CFA-negative
subgroup, LE stage amelioration was significantly more frequent in the doxycycline arm
than in the amoxicillin (<italic>P&#x000a0;</italic>=&#x000a0;.009) and placebo
(<italic>P&#x000a0;</italic>=&#x000a0;.004) arms after just 12 months, and this trend was confirmed in
both subgroups after 24 months. There was no difference between amoxicillin and placebo
in either subgroup at 12 and 24 months.</p></sec></sec><sec id="s2d"><title>Secondary Outcome Analyses</title><sec id="s2d1"><title>Acute Attacks</title><p>At 3 months, 2 patients in the amoxicillin arm (5.7%) reported acute attacks since
treatment end, compared to 12 (26.7%) in the doxycycline (<italic>P</italic>&#x000a0;=&#x000a0;.018) and
12 (31.6%) in the placebo arm (<italic>P</italic>&#x000a0;=&#x000a0;.007; Figure <xref ref-type="fig" rid="CIS486F3">3</xref>, <xref ref-type="supplementary-material" rid="sup1">Supplementary Table 5</xref>). No attacks until 24 months were reported by 46.1% in
the doxycycline, 32.3% in the amoxicillin, and 16.7% in the placebo arm. With regard to
the whole observation period a difference could be verified between the doxycycline and
placebo arms (<italic>P</italic>&#x000a0;=&#x000a0;.015) and between the amoxicillin and placebo arms
(<italic>P</italic>&#x000a0;=&#x000a0;.006) but not between the doxycycline and amoxicillin arms.</p></sec><sec id="s2d2"><title>Ultrasound Examinations of the Ankles</title><p>There was a significant decrease in skin thickness in doxycycline-treated patients
after 12 and 24 months (<italic>P</italic>&#x000a0;=&#x000a0;.008 and <italic>P</italic>&#x000a0;=&#x000a0;.001,
respectively; <xref ref-type="supplementary-material" rid="sup1">Supplementary Table
6</xref>) but no change in the amoxicillin- or placebo-treated patients. At 24 months,
skin thickness was significantly more reduced in the doxycycline arm than in the
amoxicillin arm (<italic>P</italic>&#x000a0;=&#x000a0;.019) or the placebo arm
(<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;.001; Figure&#x000a0;<xref ref-type="fig" rid="CIS486F4">4</xref>). The
measurement showed a positive correlation with the pretreatment LE severity
(<italic>r</italic>&#x000a0;=&#x000a0;0.719; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;.001), and, in contrast to the
circumference measurement, it was possible to determine a positive correlation between
thickness and LE stage 2 years after treatment (<italic>r&#x000a0;</italic>=&#x000a0;0.555;
<italic>P&#x000a0;</italic>&#x0003c;&#x000a0;.001).</p></sec><sec id="s2d3"><title>Vascular Endothelial Growth Factors</title><p>Regarding soluble VEGFR-3, a significant decrease between pretreatment and 24-month
values could be detected in doxycycline- and amoxicillin-treated patients
(<italic>P</italic>&#x000a0;=&#x000a0;.001 and <italic>P</italic>&#x000a0;=&#x000a0;.009, respectively), in contrast
to placebo-treated patients. At 24 months, the difference between doxycycline and
placebo arms was significant (<italic>P</italic>&#x000a0;=&#x000a0;.048), suggesting a superior effect
for doxycycline (<xref ref-type="supplementary-material" rid="sup1">Supplementary Figure
5</xref>). The measurements of VEGF-C showed no significant difference between
treatment groups.</p></sec><sec id="s2d4"><title>Circumference Measurement of Legs</title><p>There was no significant difference between the 3 treatment arms regarding the
circumference of legs when all patients where analyzed, nor when we limited the analysis
to LE stage 2 and 3 (data not shown).</p></sec><sec id="s2d5"><title>Foot Care and Hygiene Measures</title><p>Of 105 patients present at 24 months, 34 showed improved hygiene and only 15 showed
worsened hygiene. Most of the patients with improvement were in the placebo group
(41.2%), whereas 40% of patients with worsened hygiene were in the amoxicillin group
(<xref ref-type="supplementary-material" rid="sup1">Supplementary Table 7</xref>).</p></sec></sec><sec id="s2e"><title>Adverse Events</title><p>The total number of adverse events was equally distributed among the treatment arms. No
serious adverse events occurred during treatment.</p></sec></sec><sec sec-type="discussion" id="s3"><title>DISCUSSION</title><p>The major outcome of this trial is that a 6-week course of doxycycline, in addition to
basic morbidity management through hygiene, led to a significant improvement in the severity
of LE in both patients with and those without active infection. A similar course of
amoxicillin failed to cause such long-term improvement in LE severity, although it did lead
to fewer acute attacks and an initial improvement in LE severity, which, however, was not
sustained. These findings extend the benefit of doxycycline therapy to the majority of
affected patients with LE, independent of their infection status, and offers the opportunity
to broaden the scope of care for improved morbidity management in LF.</p><p>The improvement in LE severity was observed in patients with LE stage 1&#x02013;3, but not in those
with LE stage 4 or 5, suggesting that doxycycline is primarily active against early LE
stages and that its benefits do not extend to stages in which extensive fibrotic tissue
growth, skin thickening, and restructuring have already occurred. However, because patients
with higher-stage LE were few (stage 4&#x02013;5) or not included in this study (stage 6&#x02013;7),
additional trials would be needed to extend a benefit of doxycycline to those patients. The
improvements observed in patients without active infection suggest that the therapeutic
activity of doxycycline is not restricted to its known anti-<italic>Wolbachia</italic> or
macrofilaricidal activities.</p><p>The lack of progression of LE and the reduction in acute dermatolymphangioadenitis attacks,
especially during the first 3 months after begin of amoxicillin treatment, suggest that
there may be 2 distinct benefits from treatment, the first related to reduction in bacterial
load achieved by both doxycycline and amoxicillin and the other related to doxycycline's
additional nonantibiotic mode of action, which includes the inhibition of inflammation,
angiogenesis, proteolysis, and apoptosis [<xref rid="CIS486C13" ref-type="bibr">13&#x02013;18</xref>]. Soluble VEGFR-3 is a marker found in a previous study [<xref rid="CIS486C7" ref-type="bibr">7</xref>] to be elevated in patients with LE compared with
microfilaremic asymptomatic patients with LF. Its greater decrease in the doxycycline group,
confirming earlier results, underscores the inhibition of angiogenesis by doxycycline.
Therefore, should the activity of doxycycline be independent of the antifilarial or
antibiotic mode of action, then doxycycline treatment may be further explored in nonfilarial
LE. Amoxicillin may be given to halt the progression of LE in patients who cannot take
doxycycline, such as pregnant women.</p><p>Acute attacks were reduced in all arms as anticipated based on the known effects of basic
LE management through hygiene [<xref rid="CIS486C5" ref-type="bibr">5</xref>]. Over the
whole observation period, both amoxicillin and doxycycline groups showed a reduction in the
frequency of acute attacks, consistent with the secondary bacterial etiology of acute
attacks [<xref rid="CIS486C2" ref-type="bibr">2</xref>].</p><p>Scaling up the implementation of basic LE morbidity management and increasing the scope of
care are key priorities for GPELF during the second decade of the program [<xref rid="CIS486C1" ref-type="bibr">1</xref>]. The addition of doxycycline as a complementary
therapy may, through demonstration of improved outcomes, encourage both national and local
efforts to implement morbidity management and increase MDA compliance and may also lead to
more rapid and sustained improvements in morbidity management. The additional benefits of
doxycycline regarding hydrocele [<xref rid="CIS486C19" ref-type="bibr">19</xref>] and its
macrofilaricidal activity in patients with active infection [<xref rid="CIS486C7" ref-type="bibr">7</xref>, <xref rid="CIS486C20" ref-type="bibr">20</xref>, <xref rid="CIS486C21" ref-type="bibr">21</xref>] would further enhance its effectiveness in
morbidity management. The use of doxycycline in patients with LE would not be subject to the
same constraints that prevent its use in MDA, and contraindications in children (usually
&#x0003e;9 years old when LE begins) and pregnant women may be manageable in patients with LE.
Tolerability and adverse events were the same in all treatment arms, which, together with
our experience in all previous trials [<xref rid="CIS486C7" ref-type="bibr">7</xref>, <xref rid="CIS486C19" ref-type="bibr">19&#x02013;22</xref>], shows that doxycycline is well
tolerated and safe.</p><p>In conclusion, this trial clearly demonstrates that doxycycline is beneficial in reverting
or halting the progression of early stages of filarial LE, regardless of whether there is
still active infection. These findings lead us to recommend that individuals with filarial
LE stage 1&#x02013;3 should take a course of doxycycline (200&#x000a0;mg/d) for 6 weeks every other year, or
maybe even yearly, and that doxycycline should be considered as a new tool to improve
morbidity management of LE.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sup1"><label>Supplementary Data</label><media xlink:href="cis486_Supplementary_Data.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplementary Data</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_55_5_621__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="msword"
xlink:href="supp_cis486_cis486supp.doc"/>
</supplementary-material>
</sec></body><back><ack><title>Notes</title><p>
<bold><italic>Acknowledgments.</italic></bold>&#x02003;We thank Dr Susanne Deininger and Kathrin Arndts for measuring immunological
parameters and Dr Laura Layland for critical reading of the manuscript.</p><p>
<bold><italic>Financial support.</italic></bold>&#x02003;This work was supported by the Volkswagen Foundation, Hannover, Germany (grant I/81
306 and I/84 159 &#x0201c;Communicable Diseases in Sub-Saharan Africa: From the African Bench to the
Field&#x0201d;) and as part of the A-WOL consortium by the Liverpool School of Tropical Medicine,
through a grant from the Bill and Melinda Gates Foundation (grant 39284).</p><p>
<bold><italic>Potential conflicts of interest.</italic></bold>&#x02003;All authors: No reported conflicts.</p><p>All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of
Interest. Conflicts that the editors consider relevant to the content of the manuscript have
been disclosed.</p></ack><ref-list><title>References</title><ref id="CIS486C1"><label>1</label><element-citation publication-type="journal"><collab>WHO</collab><article-title>GPELF progress report 2000-2009 and strategic plan
2010&#x02013;2020</article-title><comment>Available at: <uri xlink:type="simple" xlink:href="http://www.who.int/neglected_diseases/integrated_media/integrated_media_urogenital_lf_2011/en/index.html">http://www.who.int/neglected_diseases/integrated_media/integrated_media_urogenital_lf_2011/en/index.html</uri>
Accessed 23 May 2012</comment></element-citation></ref><ref id="CIS486C2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dreyer</surname><given-names>G</given-names></name><name><surname>Medeiros</surname><given-names>Z</given-names></name><name><surname>Netto</surname><given-names>MJ</given-names></name><name><surname>Leal</surname><given-names>NC</given-names></name><name><surname>de Castro</surname><given-names>LG</given-names></name><name><surname>Piessens</surname><given-names>WF</given-names></name></person-group><article-title>Acute attacks in the extremities of persons living in an area endemic for
bancroftian filariasis: differentiation of two syndromes</article-title><source>Trans R Soc Trop Med Hyg</source><year>1999</year><volume>93</volume><fpage>413</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10674092</pub-id></element-citation></ref><ref id="CIS486C3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Addiss</surname><given-names>DG</given-names></name><name><surname>Brady</surname><given-names>MA</given-names></name></person-group><article-title>Morbidity management in the Global Programme to Eliminate Lymphatic
Filariasis: a review of the scientific literature</article-title><source>Filaria J</source><year>2007</year><volume>6</volume><fpage>2</fpage><pub-id pub-id-type="pmid">17302976</pub-id></element-citation></ref><ref id="CIS486C4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Addiss</surname><given-names>D</given-names></name></person-group><article-title>The 6th Meeting of the Global Alliance to Eliminate Lymphatic Filariasis: a
half-time review of lymphatic filariasis elimination and its integration with the
control of other neglected tropical diseases</article-title><source>Parasit Vectors</source><year>2010</year><volume>3</volume><fpage>100</fpage><pub-id pub-id-type="pmid">20961435</pub-id></element-citation></ref><ref id="CIS486C5"><label>5</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Dreyer</surname><given-names>G</given-names></name><name><surname>Addiss</surname><given-names>D</given-names></name><name><surname>Dreyer</surname><given-names>P</given-names></name><name><surname>Noroes</surname><given-names>J</given-names></name></person-group><source>Basic lymphoedema management: treatment and prevention of problems associated with
lymphatic filariasis</source><year>2002</year><publisher-loc>Hollis, NH</publisher-loc><publisher-name>Hollis Publishing</publisher-name></element-citation></ref><ref id="CIS486C6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dreyer</surname><given-names>G</given-names></name><name><surname>Noroes</surname><given-names>J</given-names></name><name><surname>Amaral</surname><given-names>F</given-names></name><etal/></person-group><article-title>Direct assessment of the adulticidal efficacy of a single dose of
ivermectin in bancroftian filariasis</article-title><source>Trans R Soc Trop Med Hyg</source><year>1995</year><volume>89</volume><fpage>441</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">7570894</pub-id></element-citation></ref><ref id="CIS486C7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debrah</surname><given-names>AY</given-names></name><name><surname>Mand</surname><given-names>S</given-names></name><name><surname>Specht</surname><given-names>S</given-names></name><etal/></person-group><article-title>Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in
lymphatic filariasis</article-title><source>PLoS Pathog</source><year>2006</year><volume>2</volume><fpage>e92</fpage><pub-id pub-id-type="pmid">17044733</pub-id></element-citation></ref><ref id="CIS486C8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunyo</surname><given-names>SK</given-names></name><name><surname>Nkrumah</surname><given-names>FK</given-names></name><name><surname>Simonsen</surname><given-names>PE</given-names></name></person-group><article-title>Single-dose treatment of <italic>Wuchereria bancrofti</italic> infections
with ivermectin and albendazole alone or in combination: evaluation of the potential for
control at 12&#x000a0;months after treatment</article-title><source>Trans R Soc Trop Med Hyg</source><year>2000</year><volume>94</volume><fpage>437</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">11127253</pub-id></element-citation></ref><ref id="CIS486C9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gbakima</surname><given-names>AA</given-names></name><name><surname>Appawu</surname><given-names>MA</given-names></name><name><surname>Dadzie</surname><given-names>S</given-names></name><etal/></person-group><article-title>Lymphatic filariasis in Ghana: establishing the potential for an urban
cycle of transmission</article-title><source>Trop Med Int Health</source><year>2005</year><volume>10</volume><fpage>387</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">15807803</pub-id></element-citation></ref><ref id="CIS486C10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shenoy</surname><given-names>RK</given-names></name><name><surname>Kumaraswami</surname><given-names>V</given-names></name><name><surname>Suma</surname><given-names>TK</given-names></name><name><surname>Rajan</surname><given-names>K</given-names></name><name><surname>Radhakuttyamma</surname><given-names>G</given-names></name></person-group><article-title>A double-blind, placebo-controlled study of the efficacy of oral
penicillin, diethylcarbamazine or local treatment of the affected limb in preventing
acute adenolymphangitis in lymphoedema caused by brugian filariasis</article-title><source>Ann Trop Med Parasitol</source><year>1999</year><volume>93</volume><fpage>367</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">10656038</pub-id></element-citation></ref><ref id="CIS486C11"><label>11</label><element-citation publication-type="journal"><collab>WHO</collab><article-title>Lymphatic Filariasis: the disease and its control</article-title><source>Tech Rep Ser</source><year>1992</year><comment>821:1&#x02013;71</comment></element-citation></ref><ref id="CIS486C12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mand</surname><given-names>S</given-names></name><name><surname>Marfo-Debrekyei</surname><given-names>Y</given-names></name><name><surname>Dittrich</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>K</given-names></name><name><surname>Adjei</surname><given-names>O</given-names></name><name><surname>Hoerauf</surname><given-names>A</given-names></name></person-group><article-title>Animated documentation of the filaria dance sign (FDS) in bancroftian
filariasis</article-title><source>Filaria J</source><year>2003</year><volume>2</volume><fpage>3</fpage><pub-id pub-id-type="pmid">12636874</pub-id></element-citation></ref><ref id="CIS486C13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monk</surname><given-names>E</given-names></name><name><surname>Shalita</surname><given-names>A</given-names></name><name><surname>Siegel</surname><given-names>DM</given-names></name></person-group><article-title>Clinical applications of non-antimicrobial tetracyclines in
dermatology</article-title><source>Pharmacol Res</source><year>2011</year><volume>63</volume><fpage>130</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">20937386</pub-id></element-citation></ref><ref id="CIS486C14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sapadin</surname><given-names>AN</given-names></name><name><surname>Fleischmajer</surname><given-names>R</given-names></name></person-group><article-title>Tetracyclines: nonantibiotic properties and their clinical
implications</article-title><source>J Am Acad Dermatol</source><year>2006</year><volume>54</volume><fpage>258</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">16443056</pub-id></element-citation></ref><ref id="CIS486C15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soory</surname><given-names>M</given-names></name></person-group><article-title>A role for non-antimicrobial actions of tetracyclines in combating
oxidative stress in periodontal and metabolic diseases: a literature
review</article-title><source>Open Dent J</source><year>2008</year><volume>2</volume><fpage>5</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">19088876</pub-id></element-citation></ref><ref id="CIS486C16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fainaru</surname><given-names>O</given-names></name><name><surname>Adini</surname><given-names>I</given-names></name><name><surname>Benny</surname><given-names>O</given-names></name><etal/></person-group><article-title>Doxycycline induces membrane expression of VE-cadherin on endothelial cells
and prevents vascular hyperpermeability</article-title><source>FASEB J</source><year>2008</year><volume>22</volume><fpage>3728</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">18606869</pub-id></element-citation></ref><ref id="CIS486C17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fainaru</surname><given-names>O</given-names></name><name><surname>Hornstein</surname><given-names>MD</given-names></name><name><surname>Folkman</surname><given-names>J</given-names></name></person-group><article-title>Doxycycline inhibits vascular leakage and prevents ovarian hyperstimulation
syndrome in a murine model</article-title><source>Fertil Steril</source><year>2009</year><volume>92</volume><fpage>1701</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">18937946</pub-id></element-citation></ref><ref id="CIS486C18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golub</surname><given-names>LM</given-names></name><name><surname>Ramamurthy</surname><given-names>NS</given-names></name><name><surname>McNamara</surname><given-names>TF</given-names></name><name><surname>Greenwald</surname><given-names>RA</given-names></name><name><surname>Rifkin</surname><given-names>BR</given-names></name></person-group><article-title>Tetracyclines inhibit connective tissue breakdown: new therapeutic
implications for an old family of drugs</article-title><source>Crit Rev Oral Biol Med</source><year>1991</year><volume>2</volume><fpage>297</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">1654139</pub-id></element-citation></ref><ref id="CIS486C19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debrah</surname><given-names>AY</given-names></name><name><surname>Mand</surname><given-names>S</given-names></name><name><surname>Marfo-Debrekyei</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Reduction in levels of plasma vascular endothelial growth factor-A and
improvement in hydrocele patients by targeting endosymbiotic <italic>Wolbachia</italic>
sp. in <italic>Wuchereria bancrofti</italic> with doxycycline</article-title><source>Am J Trop Med Hyg</source><year>2009</year><volume>80</volume><fpage>956</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">19478258</pub-id></element-citation></ref><ref id="CIS486C20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mand</surname><given-names>S</given-names></name><name><surname>Pfarr</surname><given-names>K</given-names></name><name><surname>Sahoo</surname><given-names>PK</given-names></name><etal/></person-group><article-title>Macrofilaricidal activity and amelioration of lymphatic pathology in
bancroftian filariasis after 3&#x000a0;weeks of doxycycline followed by single-dose
diethylcarbamazine</article-title><source>Am J Trop Med Hyg</source><year>2009</year><volume>81</volume><fpage>702</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">19815891</pub-id></element-citation></ref><ref id="CIS486C21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>MJ</given-names></name><name><surname>Makunde</surname><given-names>WH</given-names></name><name><surname>McGarry</surname><given-names>HF</given-names></name><name><surname>Turner</surname><given-names>JD</given-names></name><name><surname>Mand</surname><given-names>S</given-names></name><name><surname>Hoerauf</surname><given-names>A</given-names></name></person-group><article-title>Macrofilaricidal activity after doxycycline treatment of <italic>Wuchereria
bancrofti:</italic> a double-blind, randomised placebo-controlled
trial</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>2116</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">15964448</pub-id></element-citation></ref><ref id="CIS486C22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoerauf</surname><given-names>A</given-names></name><name><surname>Volkmann</surname><given-names>L</given-names></name><name><surname>Hamelmann</surname><given-names>C</given-names></name><etal/></person-group><article-title>Endosymbiotic bacteria in worms as targets for a novel chemotherapy in
filariasis</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>1242</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">10770311</pub-id></element-citation></ref></ref-list></back></article>